Veracyte, Inc. (VCYT)
| Market Cap | 4.17B +44.3% |
| Revenue (ttm) | 561.90M +17.3% |
| Net Income | 114.48M +334.7% |
| EPS | 1.39 +315.4% |
| Shares Out | 80.39M |
| PE Ratio | 37.19 |
| Forward PE | 29.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 603,583 |
| Open | 48.06 |
| Previous Close | 48.20 |
| Day's Range | 47.33 - 51.79 |
| 52-Week Range | 29.46 - 60.91 |
| Beta | 1.95 |
| Analysts | Strong Buy |
| Price Target | 59.73 (+15.18%) |
| Earnings Date | Nov 4, 2026 |
About VCYT
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its n... [Read more]
Financial Performance
In 2025, Veracyte's revenue was $517.15 million, an increase of 16.01% compared to the previous year's $445.76 million. Earnings were $66.35 million, an increase of 174.89%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for VCYT stock is "Strong Buy." The 12-month stock price target is $59.73, which is an increase of 15.18% from the latest price.
News
Phase III Trial Shows Veracyte's Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer
STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO STAMPEDE study analysis providing new predictive evidence in clini...
Six Studies to Highlight Veracyte's Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that six studies involving its genomic tests will be...
Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test
Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer Milestone supports broader U.S. adoption of Prosigna and expands access for...
Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third...
Cathie Wood’s ARK Investment buys 115.5K shares of Veracyte today
20:23 EDT Cathie Wood’s ARK Investment buys 115.5K shares of Veracyte (VCYT) today
Cathie Wood’s ARK Investment buys 159K shares of Veracyte today
20:18 EDT Cathie Wood’s ARK Investment buys 159K shares of Veracyte (VCYT) today
Veracyte announces new findings from Phase III NRG/RTOG 0815 trial
Veracyte (VCYT) announced that new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial will be presented at the 2026 American Society for Radiation Oncolog...
Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new findings from a retrospective ancillary analysis...
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
Six oral presentations and two posters will highlight Decipher's prognostic and predictive value in identifying patients' risk of progression and likelihood of benefiting from treatment intensificatio...
Veracyte Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The event highlighted a strategic acquisition to expand the bladder cancer portfolio, strong growth in Decipher and Afirma tests, and the launch of new products like Prosigna and TrueMRD. Operational synergies, robust evidence generation, and a balanced reinvestment approach underpin a positive financial outlook.
Veracyte acquires Convergent Genomics for $150M in cash upfront
Veracyte (VCYT) announced its acquisition of Convergent Genomics. The acquisition adds Convergent Genomics’ UroAmp platform, including its proprietary urinary tumor DNA technology, to Veracyte’s produ...
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey Acquisition positions Veracyte to deliver...
Veracyte assumed with a Buy at UBS
UBS assumed coverage of Veracyte (VCYT) with a Buy rating and $65 price target Veracyte is well positioned to deliver sustainable revenue growth and continued margin expansion, with a clear…
Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will participate in a fireside chat at the Morga...
Cathie Wood’s ARK Investment buys 47.8K shares of Veracyte today
20:20 EDT Cathie Wood’s ARK Investment buys 47.8K shares of Veracyte (VCYT) today
Veracyte Transcript: Canaccord Genuity's 46th Annual Growth Conference
Q2 saw strong revenue and margin performance, driven by new launches in breast cancer and MRD. Decipher remains a growth engine despite guideline headwinds, while Afirma and Prosigna benefit from operational and clinical advances. Strategic focus is on high-ROIC investments and international expansion.
Veracyte price target lowered to $44 from $47 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Veracyte (VCYT) to $44 from $47 and keeps an Underweight rating on the shares.
Veracyte price target lowered to $55 from $68 at Stephens
Stephens lowered the firm’s price target on Veracyte (VCYT) to $55 from $68 and keeps an Overweight rating on the shares. Shares sold off about 20% after the Q2 report…
Veracyte price target lowered to $54 from $66 at Piper Sandler
Piper Sandler lowered the firm’s price target on Veracyte (VCYT) to $54 from $66 following quarterly results. The firm keeps an Overweight rating on the shares.
Veracyte price target lowered to $50 from $60 at Canaccord
Canaccord analyst Kyle Mikson lowered the firm’s price target on Veracyte (VCYT) to $50 from $60 and keeps a Hold rating on the shares. The firm said its target decrease…
Veracyte price target raised to $69 from $57 at Needham
Needham raised the firm’s price target on Veracyte (VCYT) to $69 from $57 and keeps a Buy rating on the shares after its Q2 earnings beat. Gross margin was up…
Veracyte raises FY26 revenue view to $590M-$596M from $582M-$592M
Consensus $585.45M. The company said, “The company is raising 2026 total revenue guidance to $590 million to $596 million, or 14% to 15% growth, from prior guidance of $582 to…
Veracyte reports Q2 EPS 54c, consensus 43c
Reports Q2 revenue $150.3M, consensus $144.48M. “Q2 was a milestone quarter for Veracyte (VCYT) as we launched two new products, Prosigna LDT and TrueMRD for MIBC, while also delivering strong…